Consideraciones sobre el uso de inmunoterapia intravesical con Mycobacterium bovis variedad bacilo Calmette Guérin en el tratamiento del carcinoma vesical

Cameo, María Isabel; Lezcano, María Antonia.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 28(10): 761-762, dic. 2010.
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-95364

Documentos relacionados

  1. Clinical presentation of bacille Calmette-Guérin (BCG) infections after BCG instillation therapy.
  2. Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.
  3. [Immunotherapy of Urothelial Carcinoma of the Bladder -  from BCG Vaccines to Targeted Therapy].
  4. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
  5. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
  6. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
  7. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer.
  8. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
  9. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
  10. Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.